IFIH1 and juvenile dermatomyositis: First, compared with previous cross-sectional or case–control studies (4, 15, 22), our cohort permitted the analysis of identified predictors to screen anti-MDA5 antibodies in JDM patients by establishing an evaluation system rather than identifying and concentrating on isolated risk factors.